SCHEMBL1005181

SCHEMBL1005181

O=C1CCC2CC12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1101567 1.00
SCHEMBL15829440 1.00
SCHEMBL16299977 1.00
SCHEMBL1515575 1.00
SCHEMBL1515508 1.00
SCHEMBL1516163 1.00
SCHEMBL62747 0.83
SCHEMBL87331 0.83
SCHEMBL21027179 0.81
SCHEMBL1780491 0.79 KMT2A (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016085941-A1 PROCESSES FOR THE PREPARATION OF CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. (US) 2016-06-02 WO claimed
EP-0003666-B1 OXABICYCLO 3.1.0 HEXANES USEFUL IN THE PRODUCTION OF CYCLOPROPANECARBOXYLATE INSECTICIDES AND INTERMEDIATE COMPOUNDS FMC Corporation (US) 1983-04-06 EP claimed
EP-4680609-A1 KRAS MODULATORS AND USES THEREOF Quanta Therapeutics, Inc. (US) 2026-01-21 EP disclosed
US-20260008789-A1 KRAS MODULATORS AND USES THEREOF QUANTA THERAPEUTICS INC (US) 2026-01-08 US disclosed
US-12421254-B2 KRAS modulators and uses thereof QUANTA THERAPEUTICS, INC. (US) 2025-09-23 US disclosed
US-20250243222-A1 PYRIMIDINE BASED MODULATORS AND USES THEREOF QUANTA THERAPEUTICS, INC. 2025-07-31 US disclosed
WO-2025106905-A1 COMBINATION THERAPIES WITH A KRAS MODULATOR AND AN IMMUNOMODULATOR INHIBITOR QUANTA THERAPEUTICS, INC. (US) 2025-05-22 WO disclosed
WO-2025106901-A1 COMBINATION CANCER THERAPIES WITH A KRAS MODULATOR AND AN RTK-MAPK PATHWAY INHIBITOR QUANTA THERAPEUTICS, INC. (US) 2025-05-22 WO disclosed
EP-4532494-A1 PYRIMIDINE BASED MODULATORS AND USES THEREOF Quanta Therapeutics, Inc. (US) 2025-04-09 EP disclosed
CN-119604501-A Pyrimidine-based modulators and uses thereof 光达治疗公司 2025-03-11 CN disclosed
US-20250051365-A1 KRAS MODULATORS AND USES THEREOF QUANTA THERAPEUTICS, INC. 2025-02-13 US disclosed
US-20020016492-A1 Process for preparing 3-hydroxymethyl-4-(aryl or heterocyclic)-cyclopentanones MERCK SHARP & DOHME CORP. 2002-02-07 US disclosed
US-5439874-A Preemergence, postemergence herbicides BAYER AKTIENGESELLSCHAFT (DE) 1995-08-08 US disclosed
EP-0581132-A2 Substituted Bicyclo[3.1.0]hexanes and their use as herbicide BAYER AG (DE) 1994-02-02 EP disclosed
US-4658043-A Ethers of pantolactone ROUSSEL UCLAF (FR) 1987-04-14 US disclosed
US-4540797-A Process for resolution of chiral alcohols or phenols or chiral lactonic compounds ROUSSEL UCLAF (FR) 1985-09-10 US disclosed
US-4374257-A Novel ethers containing a lactone group and a chiral atom ROUSSEL UCLAF (FR) 1983-02-15 US disclosed
EP-0023454-A2 Process for the preparation of 6,6-dimethyl-4-hydroxy-3-oxabicyclo(3.1.0)hexan-2-one and its ethers of all possible stereoisomeric forms ROUSSEL-UCLAF (FR) 1981-02-04 EP disclosed
US-4064258-A Thiazole cardiovascular agents SYNTEX (U.S.A.) INC. (US) 1977-12-20 US disclosed
US-3987087-A ANTI-ULCER, NASAL PATENCY, WOUND HEALING, LABOR INDUCEMENT THE UPJOHN COMPANY (US) 1976-10-19 US disclosed